HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy

Clin Gastroenterol Hepatol. 2017 Feb;15(2):307-309. doi: 10.1016/j.cgh.2016.09.139. Epub 2016 Sep 23.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Naphthylamine
  • Anilides / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Carbamates / therapeutic use
  • Cyclopropanes
  • DEAD-box RNA Helicases
  • Disease Progression
  • Drug Combinations
  • Drug Resistance, Viral / genetics*
  • Hepacivirus / genetics*
  • Hepatitis C, Chronic / drug therapy*
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Lactams, Macrocyclic
  • Macrocyclic Compounds / therapeutic use
  • Male
  • Middle Aged
  • Nucleoside-Triphosphatase
  • Proline / analogs & derivatives
  • RNA, Viral / genetics
  • RNA-Dependent RNA Polymerase
  • Ribavirin / therapeutic use
  • Ritonavir / therapeutic use
  • Serine Endopeptidases
  • Sulfonamides / therapeutic use
  • Sustained Virologic Response
  • Treatment Failure
  • Uracil / analogs & derivatives
  • Uracil / therapeutic use
  • Valine
  • Viral Nonstructural Proteins / genetics
  • Viral Proteases

Substances

  • 2-Naphthylamine
  • Anilides
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Drug Combinations
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Proline
  • RNA, Viral
  • Ribavirin
  • Ritonavir
  • Sulfonamides
  • Uracil
  • Valine
  • Viral Nonstructural Proteins
  • NS3 protein, hepatitis C virus
  • Serine Endopeptidases
  • Nucleoside-Triphosphatase
  • DEAD-box RNA Helicases
  • Viral Proteases
  • ombitasvir
  • dasabuvir
  • NS-5 protein, hepatitis C virus
  • RNA-Dependent RNA Polymerase
  • paritaprevir